NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...
Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.
Nomination recognizes synseer's mission to transform the ear into a continuous health-intelligence platform helping people understand, manage and extend their healthspan.
First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.
Boston Industrial Solutions announces the launch of SAP-G70 Silicone Primer, designed for effective bonding of silicone to silicone and various other materials.
Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Natural Field, a nutraceutical ingredient manufacturer specializing in innovative delivery systems, unveiled NF TriSolve® at CPHI China 2026, showcasing its latest advancement in science-driven nutritional formulation solutions.
As Southern Nevada public systems face mounting pressure, families seeking timely answers after the death of a loved one are often left waiting in uncertainty.
A growing number of families in Phoenix and across Arizona are seeking independent medical examinations through private autopsy services to find definitive answers following the loss of a loved one.
First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)
An open Bayesian Causal Atlas now reports, for every disease it covers — including non-fatal conditions — the best-case modelled reduction achievable when all applicable beneficial interventions are combined under a Pearl structural-causal framework.
NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...
Neurogut Inc. is proud to announce the granting of US Patent US12575788B2 for its Bioanatoner device, a groundbreaking biofeedback system designed to transform the treatment of anorectal and pelvic floor disorders.
Independent analysis finds Zenkuda more likely than not to achieve non-inferiority, while the quality of vision preservation and achieved dosing durability could produce materially different commercial and valuation outcomes.
MARKET OVERVIEW: Precision fermentation is moving beyond alternative dairy into collagen, nutraceuticals, functional nutrition and specialty ingredients.
Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.
Metavalis Inc. details advanced R&D across genomic radioprotection, neural interfacing, and cryopreservation, powered by the A.L.I.C.E. computational platform.
Nomination recognizes synseer's mission to transform the ear into a continuous health-intelligence platform helping people understand, manage and extend their healthspan.
Independent analysis finds ulixacaltamide approval increasingly likely, while identifying residual FDA uncertainty and post-approval commercial persistence as underappreciated risks.
The strategic capital injection will scale biological payloads and expand the V18 Prometheus neural topology of the world's most powerful AI, A.L.I.C.E.
First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.
Boston Industrial Solutions announces the launch of SAP-G70 Silicone Primer, designed for effective bonding of silicone to silicone and various other materials.
Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Pythia BioSciences and Lexogen recently announced a strategic partnership to empower researchers with deeper biological insights by combining Lexogen's expertise in RNA sequencing and library preparation with Pythia's multi-omics data curation and...
Relaxation with flow of endorphins, Neurotransmitters act as natural Painkiller Dr.Abhay Kumar Pati, Physician, Researcher, Focusing on Natural Remedies Hayward, CA, USA Endorphins are the body's natural "feel-good" chemicals.
Endorphins: the "feel good" chemicals for Healthy Lifestyle Dr.Abhay Kumar Pati, An Ayurvedic Physician, Researcher, Author, Hayward, CA USA The term "endorphin" is derived from two words: "endogenous," meaning within the body and "morphine," an...
Nigiella Sativa, Black Cumin Oil Dr.Abhay Kumar Pati, An Ayurvedic Physician, Researcher, Dietary Food Formulator, Hayward, CA USA Nigiella Sativa, Black Cumin Oil, Therapeutic Properties Nigiella Sativa (Black seed )is the common name for the...
Exposed By 40 Year- QA Expert And Boeing Shareholder DARYL GUBERMAN — The Accreditation Collapse That Endangers Aircraft, Implants, Stents, Pharmaceuticals, Vehicles, Defense Systems, Energy Infrastructure, Food Production, Electronics, And Every...
Discover latest Metabolomics Market Report with insights on Metabolomics Market Size, Trends, Analysis, and Forecast to 2032. Explore how precision medicine, biomarker discovery, and advanced analytical technologies are driving global market growth.
Genomate Health, a precision oncology company developing computational reasoning technology for cancer treatment planning, today announced a research collaboration with Inflexa, a company specializing in AI-powered multi-omics analysis.
